Changes of bone turnover markers and serum PTH after night or morning administration of zoledronic acid in breast cancer patients with bone metastases

[1]  D. Generali,et al.  The circadian rhythm of biochemical markers of bone resorption is normally synchronized in breast cancer patients with bone lytic metastases independently of tumor load. , 2007, Bone.

[2]  D. Generali,et al.  Could the long-term persistence of low serum calcium levels and high serum parathyroid hormone levels during bisphosphonate treatment predispose metastatic breast cancer patients to undergo osteonecrosis of the jaw? , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[3]  F. Saad,et al.  Effect of zoledronic acid (Z) treatment based on serum parathyroid hormone (PTH) levels in patients (pts) with malignant bone disease. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  P. Stiff,et al.  Management of the adverse effects associated with intravenous bisphosphonates. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[5]  M. Seibel.  Clinical use of markers of bone turnover in metastatic bone disease , 2005, Nature Clinical Practice Oncology.

[6]  S. Cremers,et al.  Skeletal Retention of Bisphosphonate (Pamidronate) and Its Relation to the Rate of Bone Resorption in Patients With Breast Cancer and Bone Metastases , 2005, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[7]  F. Saad,et al.  Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  G. Mundy.  How can bone turnover markers be best utilized for prediction of skeletal events in patients with solid tumors? , 2005, Nature Clinical Practice Oncology.

[9]  F. Saad,et al.  Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. , 2005, Journal of the National Cancer Institute.

[10]  F. Pagani,et al.  Markers of bone turnover: biochemical and clinical perspectives. , 2005, Journal of endocrinological investigation.

[11]  L. Rosen,et al.  Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion , 2004, Cancer.

[12]  C. Caspar,et al.  Bisphosphonate induced hypocalcemia is caused by demasked vitamin D deficiency. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  L. Rosen.  New generation of bisphosphonates: broad clinical utility in breast and prostate cancer. , 2004, Oncology.

[14]  E. Shane,et al.  Prolonged hypocalcemia after treatment with zoledronic acid in a patient with prostate cancer and vitamin D deficiency. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  R. Coleman,et al.  Bone resorption predicts for skeletal complications in metastatic bone disease , 2003, British Journal of Cancer.

[16]  C. Rosen,et al.  Severe hypocalcemia after intravenous bisphosphonate therapy in occult vitamin D deficiency. , 2003, The New England journal of medicine.

[17]  G. Mundy,et al.  Mechanisms of osteolytic bone metastases in breast carcinoma , 2003, Cancer.

[18]  H. Schran,et al.  Development and validation of a highly sensitive RIA for zoledronic acid, a new potent heterocyclic bisphosphonate, in human serum, plasma and urine. , 2002, Journal of pharmaceutical and biomedical analysis.

[19]  C. Christiansen,et al.  Mechanism of circadian variation in bone resorption. , 2002, Bone.

[20]  L. Dogliotti,et al.  Incidence of skeletal complications in patients with bone metastatic prostate cancer and hormone refractory disease: predictive role of bone resorption and formation markers evaluated at baseline. , 2000, The Journal of urology.

[21]  S. Cerutti,et al.  Differential patterns of bone turnover in relation to bone pain and disease extent in bone in cancer patients with skeletal metastases. , 1999, Clinical chemistry.

[22]  J. Lin,et al.  Bisphosphonates: a review of their pharmacokinetic properties. , 1996, Bone.

[23]  F. Pi-Sunyer,et al.  The Use of Areas Under Curves in Diabetes Research , 1995, Diabetes Care.

[24]  E. Brown,et al.  Four-parameter model of the sigmoidal relationship between parathyroid hormone release and extracellular calcium concentration in normal and abnormal parathyroid tissue. , 1983, The Journal of clinical endocrinology and metabolism.